Atul Pande

Atul C.
Pande is President & Chief Executive Officer at Verity BioConsulting LLC since 2014.
Holds director roles at Roivant Sciences, Inc., Immunovant Sciences Ltd. since 2019, Immunovant, Inc. since 2019, and Non-Executive Director at Pangea Botanica Ltd. since 2022.
Former positions include Lead Independent Director at Sio Gene Therapies, Inc. from 2018 to 2023, Independent Director at Karuna Therapeutics, Inc. from 2019 to 2024, Non-Executive Director at Autifony Therapeutics Ltd. from 2013 to 2023, Non-Executive Director at Perception Neuroscience, Inc. from 2019 to 2023, Chief Medical Officer & Executive Vice President at Tal Medical, Inc. from 2014 to 2017, Senior Vice President at GSK Plc from 2007 to 2014, Chief Medical Officer at PureTech Health Plc from 2017 to 2018, Director at Nxera Pharma UK Ltd., Senior Director at Parke-Davis Pharmaceutical Research, Inc., Director at Immunovant, Inc., Vice President at Eli Lilly & Co., Vice President-Neurosciences at Pfizer Inc., Chief Medical Officer at CeNeRx BioPharma, Inc., Principal at Lilly Research Laboratories, and Assistant Professor at the University of Michigan Medical School.
Education includes undergraduate and doctorate degrees from the University of Lucknow.